Neola Medical AB (publ) (NEOLA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

This morning, Neola Medical has published a report for the second quarter of 2026. And joining us here in the digital studio, I have the company's CEO, Hanna Sjöström. Welcome. Thank you so much. You will give a presentation of the quarter's development and then I'll return to ask some questions. But before I do that, I would like to also remind our viewers that they can ask their questions in the live chat during this broadcast. So, Hanna, go ahead. HELLO EVERYONE AND WELCOME TO NIOLA MEDICAL'S PRESENTATION OF OUR SECOND QUARTER FOR 2026. I'M HANNA SCHYSTROM CEO OF NIOLA MEDICAL AND I'M JOINED TODAY BY OUR CFO DAVID FOLKESSON. Now, the second quarter represents an important step forward for Neola Medical. We have completed our first clinical pilot study in our intended patient population, preterm born babies. We have strengthened our financing and based on the clinical and preclinical evidence generated, sharpened the focus of Neola towards continuous lung monitoring with the detection of potentially life threatening lung collapse. So today I will first take you through the key developments and our strategic direction, and then I will conclude together with David with the financial perspective and take your questions. Now, before we begin, I would like to remind you that today's presentation include forward looking statements related to our strategy, market opportunity and development plans. So these are naturally subject to risk and uncertainties, including regulatory and clinical development risks. And you can read more about these risks on our website. With that, over to our presentation. for today. So there are three developments I would like to particularly highlight from the quarter. First, we reported positive safety results from our first clinical pilot stud...